Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biocryst Pharmaceuticals

9.66
-0.0800-0.82%
Post-market: 9.660.00000.00%19:55 EDT
Volume:2.56M
Turnover:24.77M
Market Cap:2.02B
PE:-37.23
High:9.81
Open:9.81
Low:9.61
Close:9.74
Loading ...

Zacks.com featured highlights ASR, INSW, BCRX, ASC and RRGB

Zacks
·
Yesterday

BioCryst Pharmaceuticals Price Target Maintained With a $17.00/Share by Needham

Dow Jones
·
25 Jun

Needham Sticks to Its Buy Rating for BioCryst (BCRX)

TIPRANKS
·
25 Jun

5 Must-Buy Efficient Stocks to Buy for Solid Gains Amid Volatility

Zacks
·
25 Jun

BioCryst Pharmaceuticals Inc - New Pdufa Target Action Date Set for December 12, 2025 - SEC Filing

THOMSON REUTERS
·
25 Jun

BioCryst Pharmaceuticals Faces FDA Review Extension for Pediatric ORLADEYO® Application, New Target Date Set for December 2025

Reuters
·
25 Jun

BioCryst Pharmaceuticals Inc. Concluded Annual Stockholders Meeting

Reuters
·
17 Jun

BioCryst announces new data on efficacy, safety of ORLADEYO

TIPRANKS
·
16 Jun

Sector Update: Health Care Stocks Lean Lower Premarket Friday

MT Newswires Live
·
13 Jun

BioCryst Pharmaceuticals Receives Approval for Orladeyo in Colombia

MT Newswires Live
·
13 Jun

BioCryst announces INVIMA in Colombia approved ORLADEYO

TIPRANKS
·
13 Jun

Orladeyo® (Berotralstat) Approved in Colombia

THOMSON REUTERS
·
13 Jun

Sector Update: Health Care Stocks Advance Premarket Friday

MT Newswires Live
·
06 Jun

Press Release: BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

Dow Jones
·
06 Jun

BioCryst reports inducement grants under Nasdaq listing rule

TIPRANKS
·
03 Jun

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
03 Jun

BioCryst Says Orladeyo Prompted 'Significant' Drop Hereditary Angioedema Attacks in Study

MT Newswires Live
·
16 May

BioCryst Pharmaceuticals Says FDA Grants Priority Review for Orladeyo in Children

MT Newswires Live
·
14 May

BRIEF-Biocryst Announces FDA Acceptance Of NDA For Orladeyo (Berotralstat) Oral Granules In Patients With Hereditary Angioedema Aged 2 To 11 Years

Reuters
·
14 May

BioCryst Gets Speedy FDA Review of Pediatric Use of Orladeyo

Dow Jones
·
14 May